Maraviroc

Maraviroc, the active ingredient in Maraviroc, is a CCR5 antagonist presented as a 150 mg tablet for oral use. It treats HIV‑1 infection in adults by preventing viral entry into host cells.

GNH USA supplies Maraviroc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maraviroc is indicated for the treatment of HIV‑1 infection, specifically targeting viruses that use the CCR5 co‑receptor.

- HIV‑1 infection (CCR5‑tropic): Used in combination with other antiretrovirals to suppress viral replication in adults. - Treatment‑experienced HIV‑1 infection: Added to regimens when resistance to other agents has developed. - Treatment‑naïve CCR5‑tropic HIV‑1 infection: Initiated as part of first‑line therapy in patients with confirmed CCR5‑tropic virus.

Maraviroc may cause a range of adverse reactions, from mild to serious. Monitoring and reporting of side effects are essential for patient safety.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, may improve with food. - Diarrhea: usually self‑limiting. - Fatigue: persistent low‑grade tiredness. - Upper respiratory tract infection: symptoms of cold or sinusitis. - Rash: non‑specific skin eruption.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe allergic reaction: anaphylaxis, angioedema. - Depression or suicidal thoughts: mood changes requiring evaluation. - Cardiovascular events: myocardial infarction or arrhythmia. - Immune reconstitution inflammatory syndrome (IRIS): worsening of opportunistic infections. - Pulmonary complications: interstitial lung disease.

Before initiating therapy with Maraviroc, clinicians should assess patient history and monitor for potential risks.

- Liver function monitoring: check transaminases regularly during treatment. - Cardiovascular assessment: evaluate for underlying heart disease before use. - Hypersensitivity screening: avoid in patients with known allergy to maraviroc. - Renal impairment caution: dose adjustment may be required in severe renal dysfunction. - Drug‑resistance testing: confirm CCR5‑tropic virus prior to prescribing. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Maraviroc interacts with several agents that affect its metabolism or efficacy.

Major Interactions (Avoid): - Ritonavir (strong CYP3A4 inhibitor): markedly increases maraviroc plasma concentrations. - Enzalutamide (strong CYP3A4 inducer): significantly reduces maraviroc exposure.

Moderate Interactions (Monitor Closely): - Efavirenz (moderate CYP3A4 inducer): may lower maraviroc levels. - Atazanavir (CYP3A4 inhibitor): can increase maraviroc concentrations. - Phenytoin (CYP3A4 inducer): may decrease maraviroc effectiveness.